QLT PhotoTherapeutics Inc., American Cyanamid Co. deal

QLTIF exercised its option to reacquire from Cyanamid the marketing and distribution rights to QLTIF's Photofrin light activated drug in countries where regulatory and pricing approvals have not been received.

QLTIF will reacquire rights in all jurisdictions except Japan, for which Cyanamid will retain exclusive rights, and Italy, where QLTIF retains the option to reacquire rights. ...